## 1. Phylogeny

IRAK4 is a member of the interleukin‐1 receptor‐associated kinase (IRAK) family, a distinct subset of serine/threonine protein kinases that play a central role in mediating early innate immune signaling events (bahia2015interleukin1receptorassociated pages 3-4). Within the human kinome, IRAK4 is positioned in the Toll/IL-1 receptor signaling cascade and is evolutionarily conserved in vertebrates, which underscores its indispensable function in host defense mechanisms against pathogens (bahia2015interleukin1receptorassociated pages 17-17). Phylogenetic analyses reveal that IRAK4 shares structural and functional similarities with its paralogs—including IRAK1, IRAK2, and the catalytically inactive IRAK3—although IRAK4 uniquely acts as the “master kinase” by initiating pivotal phosphorylation events immediately following receptor activation (reinhardt2023acriticalevaluation pages 27-27). Orthologs of IRAK4 have been identified across a broad range of vertebrate species, and despite variances in overall amino acid sequence identity when compared to non-vertebrate counterparts or even certain plant pseudokinases, the catalytic residues and the basic domain architecture necessary for its role in innate immunity have been maintained throughout evolution (paul2020genome‐wideandstructural pages 8-9). This conservation suggests that the kinase emerged early in evolution and that its mechanism of signal initiation through phosphorylation was critical for the survival of multicellular organisms challenged by infectious agents.

## 2. Reaction Catalyzed

IRAK4 catalyzes the transfer of a phosphate group from ATP to specific serine/threonine residues on its substrate proteins—a reaction that—like other protein kinases—can be represented by the generalized equation: ATP + [protein]-OH → ADP + [protein]-O-phosphate + H⁺ (bahia2015interleukin1receptorassociated pages 17-17, chaudhary2015recentadvancesin pages 1-2). In innate immune signaling, IRAK4’s principal substrate is IRAK1; phosphorylation by IRAK4 leads to an increase in IRAK1’s intrinsic kinase activity and facilitates its subsequent autophosphorylation, a process that amplifies the signal within the receptor complex (de2018mechanismofdysfunction pages 12-13). Additionally, IRAK4 phosphorylates components such as E3 ubiquitin ligases of the Pellino family (PELI1, PELI2, and PELI3); this phosphorylation event activates Pellino-mediated polyubiquitination of IRAK1, which is an essential step for the recruitment of downstream signaling molecules (bahia2015interleukin1receptorassociated pages 17-17). IRAK4 also directly phosphorylates the adaptor protein TIRAP, marking it for ubiquitination and subsequent proteasomal degradation, and targets NCF1, a component that regulates NADPH oxidase activation—a mechanism important for reactive oxygen species generation during microbial infections (seganish2016inhibitorsofinterleukin1 pages 1-6). The net result of these phosphorylation reactions is the propagation of a signaling cascade that eventually leads to the assembly of complexes containing MAP3K7/TAK1, TRAF6, and the IKK complex, culminating in the nuclear translocation of NF-κB and the induction of inflammatory gene expression.

## 3. Cofactor Requirements

IRAK4, as a serine/threonine kinase, relies on the presence of divalent metal ions for its catalytic function. In particular, Mg²⁺ ions are essential co-factors that facilitate the binding of ATP to the catalytic cleft and stabilize the transition state during phosphotransfer (bahia2015interleukin1receptorassociated pages 17-17). This requirement for Mg²⁺ is common in kinase reactions, where the metal ion coordinates with the phosphate groups of ATP and helps to correctly orient the γ-phosphate for nucleophilic attack by the hydroxyl group of a serine or threonine residue on the substrate (bothe2024discoveryofirak4 pages 17-18, seganish2016inhibitorsofinterleukin1 pages 26-30). No additional cofactors or regulatory molecules have been reported to be necessary for IRAK4’s catalytic activity, indicating that its enzymatic function adheres to the well-established principles of serine/threonine kinase biochemistry.

## 4. Substrate Specificity

The substrate specificity of IRAK4 is critical for its role in initiating innate immune responses. Its primary substrate is IRAK1, whose phosphorylation by IRAK4 dramatically increases IRAK1’s kinase activity and triggers autophosphorylation events that further propagate the signal (bahia2015interleukin1receptorassociated pages 17-17, chaudhary2015recentadvancesin pages 3-4). Furthermore, IRAK4 phosphorylates the Pellino family of E3 ubiquitin ligases (PELI1, PELI2, and PELI3), enzymes that are crucial for the polyubiquitination of IRAK1. This post-translational modification of IRAK1 serves as a scaffold for the recruitment of downstream signaling complexes including MAP3K7/TAK1 and the IKK complex (de2018mechanismofdysfunction pages 12-13). In addition to these substrates, IRAK4 phosphorylates TIRAP, an adaptor protein linked to toll/interleukin-1 receptor signaling, thereby targeting it for ubiquitination and degradation—a necessary step to modulate the overall duration of the signal (seganish2016inhibitorsofinterleukin1 pages 1-6). IRAK4 also phosphorylates NCF1, which is a regulatory subunit of NADPH oxidase, integrating signals that lead to the production of reactive oxygen species during bacterial infections (seganish2016inhibitorsofinterleukin1 pages 1-6). Although a precise consensus motif for IRAK4’s substrates has not been unequivocally defined, its activity appears to be restricted to serine/threonine residues located within regions of substrates that are exposed and capable of mediating protein–protein interactions necessary for assembling multi-component signaling complexes.

## 5. Structure

IRAK4 displays a distinct domain organization that enables it to function dually as a catalyst and a scaffold in the formation of the Myddosome complex. At the N-terminus, IRAK4 contains a Death Domain (DD) which is crucial for the homotypic interactions required for recruitment by the adaptor protein MYD88 as well as for the subsequent assembly with other IRAK family members (bahia2015interleukin1receptorassociated pages 3-4). Adjacent to the DD, a flexible linker or hinge region connects to the central kinase domain. This kinase domain adopts the classical bilobed structure common to serine/threonine kinases, featuring an N-terminal lobe primarily involved in ATP binding and a larger C-terminal lobe that harbors the catalytic machinery necessary for phosphate transfer (bahia2015interleukin1receptorassociated pages 3-4, fu2024largescaleanalysisof pages 1-3).  
Recent crystallographic studies and AlphaFold2 predictions have revealed that IRAK4’s kinase domain includes unique structural elements such as an atypical tyrosine gatekeeper residue. This residue distinguishes IRAK4 from many other kinases and is exploited in the design of selective inhibitors, as it creates an unconventional pocket adjacent to the ATP-binding site (bothe2024discoveryofirak4 pages 17-18, lange2021dimericstructureof pages 13-13). Moreover, critical motifs such as the DFG and HRD motifs that govern kinase activation are present in IRAK4; autophosphorylation of residues within the activation loop adjusts the conformation of these motifs to modulate catalytic activity (bahia2015interleukin1receptorassociated pages 5-8). The overall structure of IRAK4, with its combination of a modular protein–protein interaction domain (the DD) and a catalytic kinase domain, positions it as an essential component within transient macromolecular assemblies such as the Myddosome—a supramolecular structure critical for effective signal transduction upon receptor activation (bahia2015interleukin1receptorassociated pages 8-11).

## 6. Regulation

The regulatory mechanisms governing IRAK4 activity are multifaceted and are finely tuned in response to extracellular signals. Upon activation of Toll-like receptors (TLRs) or interleukin-1 receptors (IL-1R), adaptor protein MYD88 rapidly recruits IRAK4 through specific homotypic interactions mediated by the Death Domain, which is the first step in Myddosome assembly (bahia2015interleukin1receptorassociated pages 3-4, pereira2023regulationofinnate pages 1-2). Once recruited, IRAK4 undergoes autophosphorylation, particularly within its activation loop, a process that serves not only to enhance its catalytic efficiency but also to facilitate heterodimer interactions with IRAK1 (de2018mechanismofdysfunction pages 12-13, lange2021dimericstructureof pages 19-19). This phosphorylation is a crucial molecular switch that shifts IRAK4 from an inactive to an active conformation, thereby enabling it to phosphorylate downstream substrates.  
In addition to autophosphorylation, IRAK4 directly phosphorylates key substrates that regulate the intensity and duration of the immune response. Phosphorylation of IRAK1 results in its autophosphorylation and, through Pellino-mediated polyubiquitination, recruits the IKK complex leading to NF-κB activation (chaudhary2015recentadvancesin pages 1-2, rhyasen2015iraksignallingin pages 5-6). Moreover, IRAK4’s phosphorylation of TIRAP results in TIRAP’s ubiquitination and subsequent degradation, a feedback mechanism that attenuates the signal once it has been transmitted (seganish2016inhibitorsofinterleukin1 pages 19-22). Furthermore, phosphorylation of NCF1 by IRAK4 plays a role in modulating NADPH oxidase activity, linking receptor activation with the production of reactive oxygen species that are essential for microbial killing (seganish2016inhibitorsofinterleukin1 pages 1-6). These events are complemented by additional layers of regulation whereby downstream ubiquitin ligases are themselves regulated by phosphorylation and degradation cycles, effectively creating a tightly controlled checkpoint that prevents aberrant or prolonged inflammatory responses (seganish2016inhibitorsofinterleukin1 pages 22-26, seganish2016inhibitorsofinterleukin1 pages 26-30). Thus, both the assembly of the Myddosome and the sequence of phosphorylation and ubiquitination events ensure that IRAK4 activity is subject to precise temporal and spatial control.

## 7. Function

IRAK4 is indispensable for the initiation and propagation of innate immune responses. Once recruited to activated Toll-like receptor (TLR) and IL-1 receptor (IL-1R) complexes by MYD88, IRAK4 catalyzes phosphorylation events that are critical for triggering downstream signaling cascades (bahia2015interleukin1receptorassociated pages 3-4, pereira2023regulationofinnate pages 1-2). The phosphorylation of IRAK1 by IRAK4 activates IRAK1, which in turn becomes polyubiquitinated by Pellino family E3 ubiquitin ligases—a modification that serves as a crucial signal for the recruitment and assembly of larger multi-protein complexes, including MAP3K7/TAK1, TRAF6, and ultimately the IKK complex (mcelroy2019interleukin1receptorassociatedkinase pages 1-7, chaudhary2015recentadvancesin pages 1-2). This cascade ultimately results in the nuclear translocation of NF-κB, a transcription factor that upregulates the expression of a broad array of pro-inflammatory cytokines and chemokines involved in pathogen clearance and inflammation (rhyasen2015iraksignallingin pages 5-6).  
Beyond its role in NF-κB activation, IRAK4 also phosphorylates the adaptor protein TIRAP, marking it for ubiquitination and degradation. This process contributes to the feedback mechanisms that limit the intensity and duration of the immune response, thereby preventing excessive inflammation (seganish2016inhibitorsofinterleukin1 pages 19-22). Additionally, through phosphorylation of NCF1, IRAK4 links TLR/IL-1R signaling to the activation of NADPH oxidase complexes, resulting in the generation of reactive oxygen species that play a role in microbial killing (bahia2015interleukin1receptorassociated pages 17-17). Expression of IRAK4 is largely confined to cells of the innate immune system such as monocytes, macrophages, and dendritic cells, although its presence has also been noted in some cancer cell lines. Mutations or deficiencies in IRAK4 lead to severe impairments in TLR and IL-1R signaling, resulting in increased susceptibility to bacterial infections, particularly in early life (mcelroy2019interleukin1receptorassociatedkinase pages 1-7, seganish2016inhibitorsofinterleukin1 pages 1-6). Thus, IRAK4 serves as an essential hub within the innate immune system, coordinating the cellular response to both pathogen-associated and damage-associated signals.

## 8. Other Comments

Also known as Renal carcinoma antigen NY-REN-64, IRAK4 has drawn significant attention not only for its central role in innate immunity but also as a potential therapeutic target in inflammatory and autoimmune diseases as well as certain malignancies (bahia2015interleukin1receptorassociated pages 3-4, boraschi2018thefamilyof pages 17-18). The unique presence of a tyrosine gatekeeper residue within its kinase domain has been exploited to develop selective small-molecule inhibitors that target the ATP-binding pocket of IRAK4. Notably, compounds such as PF-06650833 have shown potent inhibition of IRAK4 activity and have advanced into clinical trials targeting conditions like rheumatoid arthritis and systemic lupus erythematosus (bothe2024discoveryofirak4 pages 17-18, seganish2016inhibitorsofinterleukin1 pages 30-34). In addition to chemical inhibition, genetic studies have illuminated the consequences of IRAK4 deficiency, which lead to impaired TLR-mediated signaling and increased susceptibility to bacterial infections—a phenotype that underscores the kinase’s non-redundant role in human immunity (mcelroy2019interleukin1receptorassociatedkinase pages 1-7, rhyasen2015iraksignallingin pages 5-6). Current research is actively exploring both kinase-dependent and kinase-independent functions of IRAK4, as well as the possibility of combining IRAK4 inhibitors with other therapeutic agents such as BTK or PI3K inhibitors to achieve synergistic effects in the treatment of certain cancers and autoimmune disorders (seganish2016inhibitorsofinterleukin1 pages 26-30). Its involvement in the regulation of NADPH oxidase through phosphorylation of NCF1 further expands its impact to controlling oxidative burst responses during infection (seganish2016inhibitorsofinterleukin1 pages 1-6). Overall, IRAK4 is recognized not only as a critical mediator of early immune signaling cascades but also as a promising pharmaceutical target whose modulation could have broad therapeutic implications in diseases characterized by dysregulated inflammation.

## 9. References

* bahia2015interleukin1receptorassociated pages 3-4
* bahia2015interleukin1receptorassociated pages 17-17
* bahia2015interleukin1receptorassociated pages 5-8
* bahia2015interleukin1receptorassociated pages 8-11
* bender2023paradigmsofreceptor pages 14-15
* boraschi2018thefamilyof pages 17-18
* bothe2024discoveryofirak4 pages 1-2
* bothe2024discoveryofirak4 pages 17-18
* chaudhary2015recentadvancesin pages 1-2
* chaudhary2015recentadvancesin pages 3-4
* de2018mechanismofdysfunction pages 12-13
* faezov2023alphafold2modelsof pages 18-20
* fu2024largescaleanalysisof pages 1-3
* hatcher2020discoveryofa pages 5-6
* lange2021dimericstructureof pages 1-3
* lange2021dimericstructureof pages 13-13
* lange2021dimericstructureof pages 19-19
* liu2021leveragingdiversedata pages 139-142
* liu2021leveragingdiversedata pages 33-36
* liu2021leveragingdiversedata pages 69-74
* mcelroy2019interleukin1receptorassociatedkinase pages 1-7
* mcelroy2019interleukin1receptorassociatedkinase pages 16-21
* mcelroy2019interleukin1receptorassociatedkinase pages 21-25
* mcelroy2019interleukin1receptorassociatedkinase pages 25-32
* paul2020genome‐wideandstructural pages 8-9
* pereira2023regulationofinnate pages 1-2
* reinhardt2023acriticalevaluation pages 27-27
* rhyasen2015iraksignallingin pages 5-6
* sadangi2020molecularcharacterizationand pages 18-22
* seganish2016inhibitorsofinterleukin1 pages 1-6
* seganish2016inhibitorsofinterleukin1 pages 19-22
* seganish2016inhibitorsofinterleukin1 pages 22-26
* seganish2016inhibitorsofinterleukin1 pages 26-30
* seganish2016inhibitorsofinterleukin1 pages 30-34

References

1. (bahia2015interleukin1receptorassociated pages 17-17): Malkeet Singh Bahia, Maninder Kaur, Pragati Silakari, and Om Silakari. Interleukin-1 receptor associated kinase inhibitors: potential therapeutic agents for inflammatory- and immune-related disorders. Cellular Signalling, 27:1039-1055, Jun 2015. URL: https://doi.org/10.1016/j.cellsig.2015.02.025, doi:10.1016/j.cellsig.2015.02.025. This article has 57 citations and is from a peer-reviewed journal.
2. (bahia2015interleukin1receptorassociated pages 3-4): Malkeet Singh Bahia, Maninder Kaur, Pragati Silakari, and Om Silakari. Interleukin-1 receptor associated kinase inhibitors: potential therapeutic agents for inflammatory- and immune-related disorders. Cellular Signalling, 27:1039-1055, Jun 2015. URL: https://doi.org/10.1016/j.cellsig.2015.02.025, doi:10.1016/j.cellsig.2015.02.025. This article has 57 citations and is from a peer-reviewed journal.
3. (bahia2015interleukin1receptorassociated pages 5-8): Malkeet Singh Bahia, Maninder Kaur, Pragati Silakari, and Om Silakari. Interleukin-1 receptor associated kinase inhibitors: potential therapeutic agents for inflammatory- and immune-related disorders. Cellular Signalling, 27:1039-1055, Jun 2015. URL: https://doi.org/10.1016/j.cellsig.2015.02.025, doi:10.1016/j.cellsig.2015.02.025. This article has 57 citations and is from a peer-reviewed journal.
4. (bahia2015interleukin1receptorassociated pages 8-11): Malkeet Singh Bahia, Maninder Kaur, Pragati Silakari, and Om Silakari. Interleukin-1 receptor associated kinase inhibitors: potential therapeutic agents for inflammatory- and immune-related disorders. Cellular Signalling, 27:1039-1055, Jun 2015. URL: https://doi.org/10.1016/j.cellsig.2015.02.025, doi:10.1016/j.cellsig.2015.02.025. This article has 57 citations and is from a peer-reviewed journal.
5. (bender2023paradigmsofreceptor pages 14-15): Kyle W. Bender and Cyril Zipfel. Paradigms of receptor kinase signaling in plants. Biochemical Journal, 480:835-854, Jun 2023. URL: https://doi.org/10.1042/bcj20220372, doi:10.1042/bcj20220372. This article has 49 citations and is from a domain leading peer-reviewed journal.
6. (boraschi2018thefamilyof pages 17-18): Diana Boraschi, Paola Italiani, Sabrina Weil, and Michael U. Martin. The family of the interleukin‐1 receptors. Immunological Reviews, 281:197-232, Jan 2018. URL: https://doi.org/10.1111/imr.12606, doi:10.1111/imr.12606. This article has 362 citations and is from a domain leading peer-reviewed journal.
7. (bothe2024discoveryofirak4 pages 1-2): Ulrich Bothe, Judith Günther, Reinhard Nubbemeyer, Holger Siebeneicher, Sven Ring, Ulf Bömer, Michaele Peters, Alexandra Rausch, Karsten Denner, Herbert Himmel, Andreas Sutter, Ildiko Terebesi, Martin Lange, Antje M. Wengner, Nicolas Guimond, Tobias Thaler, Johannes Platzek, Uwe Eberspächer, Martina Schäfer, Holger Steuber, Thomas M. Zollner, Andreas Steinmeyer, and Nicole Schmidt. Discovery of irak4 inhibitors bay1834845 (zabedosertib) and bay1830839. Journal of Medicinal Chemistry, 67:1225-1242, Jan 2024. URL: https://doi.org/10.1021/acs.jmedchem.3c01714, doi:10.1021/acs.jmedchem.3c01714. This article has 17 citations and is from a highest quality peer-reviewed journal.
8. (bothe2024discoveryofirak4 pages 17-18): Ulrich Bothe, Judith Günther, Reinhard Nubbemeyer, Holger Siebeneicher, Sven Ring, Ulf Bömer, Michaele Peters, Alexandra Rausch, Karsten Denner, Herbert Himmel, Andreas Sutter, Ildiko Terebesi, Martin Lange, Antje M. Wengner, Nicolas Guimond, Tobias Thaler, Johannes Platzek, Uwe Eberspächer, Martina Schäfer, Holger Steuber, Thomas M. Zollner, Andreas Steinmeyer, and Nicole Schmidt. Discovery of irak4 inhibitors bay1834845 (zabedosertib) and bay1830839. Journal of Medicinal Chemistry, 67:1225-1242, Jan 2024. URL: https://doi.org/10.1021/acs.jmedchem.3c01714, doi:10.1021/acs.jmedchem.3c01714. This article has 17 citations and is from a highest quality peer-reviewed journal.
9. (chaudhary2015recentadvancesin pages 1-2): Divya Chaudhary, Shaughnessy Robinson, and Donna L. Romero. Recent advances in the discovery of small molecule inhibitors of interleukin-1 receptor-associated kinase 4 (irak4) as a therapeutic target for inflammation and oncology disorders. Journal of medicinal chemistry, 58 1:96-110, Jan 2015. URL: https://doi.org/10.1021/jm5016044, doi:10.1021/jm5016044. This article has 114 citations and is from a highest quality peer-reviewed journal.
10. (chaudhary2015recentadvancesin pages 3-4): Divya Chaudhary, Shaughnessy Robinson, and Donna L. Romero. Recent advances in the discovery of small molecule inhibitors of interleukin-1 receptor-associated kinase 4 (irak4) as a therapeutic target for inflammation and oncology disorders. Journal of medicinal chemistry, 58 1:96-110, Jan 2015. URL: https://doi.org/10.1021/jm5016044, doi:10.1021/jm5016044. This article has 114 citations and is from a highest quality peer-reviewed journal.
11. (de2018mechanismofdysfunction pages 12-13): Saurav De, Fawziya Karim, Ezechielle Kiessu, Leah Cushing, Lih-Ling Lin, Pegah Ghandil, Cyrille Hoarau, Jean-Laurent Casanova, Anne Puel, and Vikram R. Rao. Mechanism of dysfunction of human variants of the irak4 kinase and a role for its kinase activity in interleukin-1 receptor signaling. Journal of Biological Chemistry, 293:15208-15220, Sep 2018. URL: https://doi.org/10.1074/jbc.ra118.003831, doi:10.1074/jbc.ra118.003831. This article has 44 citations and is from a domain leading peer-reviewed journal.
12. (faezov2023alphafold2modelsof pages 18-20): Bulat Faezov and Roland L. Dunbrack. Alphafold2 models of the active form of all 437 catalytically competent human protein kinase domains. BioRxiv, Jul 2023. URL: https://doi.org/10.1101/2023.07.21.550125, doi:10.1101/2023.07.21.550125. This article has 28 citations.
13. (fu2024largescaleanalysisof pages 1-3): Qiong Fu, Qian Liu, Rensen Zhang, Jia Chen, Hengchang Guo, Zhenhua Ming, Feng Yu, and Heping Zheng. Large-scale analysis of the n-terminal regulatory elements of the kinase domain in plant receptor-like kinase family. BMC Plant Biology, Mar 2024. URL: https://doi.org/10.1186/s12870-024-04846-7, doi:10.1186/s12870-024-04846-7. This article has 2 citations and is from a peer-reviewed journal.
14. (hatcher2020discoveryofa pages 5-6): John M. Hatcher, Guang Yang, Li Wang, Scott B. Ficarro, Sara Buhrlage, Hao Wu, Jarrod A. Marto, Steven P. Treon, and Nathanael S. Gray. Discovery of a selective, covalent irak1 inhibitor with antiproliferative activity in myd88 mutated b-cell lymphoma. ACS Medicinal Chemistry Letters, 11:2238-2243, Oct 2020. URL: https://doi.org/10.1021/acsmedchemlett.0c00378, doi:10.1021/acsmedchemlett.0c00378. This article has 23 citations and is from a peer-reviewed journal.
15. (lange2021dimericstructureof pages 1-3): Sven M. Lange, Marina I. Nelen, Philip Cohen, and Yogesh Kulathu. Dimeric structure of the pseudokinase irak3 suggests an allosteric mechanism for negative regulation. Structure, 29:238-251.e4, Mar 2021. URL: https://doi.org/10.1016/j.str.2020.11.004, doi:10.1016/j.str.2020.11.004. This article has 33 citations and is from a domain leading peer-reviewed journal.
16. (lange2021dimericstructureof pages 13-13): Sven M. Lange, Marina I. Nelen, Philip Cohen, and Yogesh Kulathu. Dimeric structure of the pseudokinase irak3 suggests an allosteric mechanism for negative regulation. Structure, 29:238-251.e4, Mar 2021. URL: https://doi.org/10.1016/j.str.2020.11.004, doi:10.1016/j.str.2020.11.004. This article has 33 citations and is from a domain leading peer-reviewed journal.
17. (lange2021dimericstructureof pages 19-19): Sven M. Lange, Marina I. Nelen, Philip Cohen, and Yogesh Kulathu. Dimeric structure of the pseudokinase irak3 suggests an allosteric mechanism for negative regulation. Structure, 29:238-251.e4, Mar 2021. URL: https://doi.org/10.1016/j.str.2020.11.004, doi:10.1016/j.str.2020.11.004. This article has 33 citations and is from a domain leading peer-reviewed journal.
18. (liu2021leveragingdiversedata pages 139-142): C Liu. Leveraging diverse data modalities to study kinase inhibitor polypharmacology. Unknown journal, 2021.
19. (liu2021leveragingdiversedata pages 33-36): C Liu. Leveraging diverse data modalities to study kinase inhibitor polypharmacology. Unknown journal, 2021.
20. (liu2021leveragingdiversedata pages 69-74): C Liu. Leveraging diverse data modalities to study kinase inhibitor polypharmacology. Unknown journal, 2021.
21. (mcelroy2019interleukin1receptorassociatedkinase pages 1-7): William T. McElroy. Interleukin-1 receptor-associated kinase 4 (irak4) inhibitors: an updated patent review (2016-2018). Expert Opinion on Therapeutic Patents, 29:243-259, Mar 2019. URL: https://doi.org/10.1080/13543776.2019.1597850, doi:10.1080/13543776.2019.1597850. This article has 55 citations and is from a peer-reviewed journal.
22. (mcelroy2019interleukin1receptorassociatedkinase pages 16-21): William T. McElroy. Interleukin-1 receptor-associated kinase 4 (irak4) inhibitors: an updated patent review (2016-2018). Expert Opinion on Therapeutic Patents, 29:243-259, Mar 2019. URL: https://doi.org/10.1080/13543776.2019.1597850, doi:10.1080/13543776.2019.1597850. This article has 55 citations and is from a peer-reviewed journal.
23. (mcelroy2019interleukin1receptorassociatedkinase pages 21-25): William T. McElroy. Interleukin-1 receptor-associated kinase 4 (irak4) inhibitors: an updated patent review (2016-2018). Expert Opinion on Therapeutic Patents, 29:243-259, Mar 2019. URL: https://doi.org/10.1080/13543776.2019.1597850, doi:10.1080/13543776.2019.1597850. This article has 55 citations and is from a peer-reviewed journal.
24. (mcelroy2019interleukin1receptorassociatedkinase pages 25-32): William T. McElroy. Interleukin-1 receptor-associated kinase 4 (irak4) inhibitors: an updated patent review (2016-2018). Expert Opinion on Therapeutic Patents, 29:243-259, Mar 2019. URL: https://doi.org/10.1080/13543776.2019.1597850, doi:10.1080/13543776.2019.1597850. This article has 55 citations and is from a peer-reviewed journal.
25. (paul2020genome‐wideandstructural pages 8-9): Anindita Paul and Narayanaswamy Srinivasan. Genome‐wide and structural analyses of pseudokinases encoded in the genome of arabidopsis thaliana provide functional insights. Proteins: Structure, Function, and Bioinformatics, 88:1620-1638, Aug 2020. URL: https://doi.org/10.1002/prot.25981, doi:10.1002/prot.25981. This article has 12 citations.
26. (pereira2023regulationofinnate pages 1-2): Milton Pereira and Ricardo T. Gazzinelli. Regulation of innate immune signaling by irak proteins. Frontiers in Immunology, Feb 2023. URL: https://doi.org/10.3389/fimmu.2023.1133354, doi:10.3389/fimmu.2023.1133354. This article has 54 citations and is from a peer-reviewed journal.
27. (reinhardt2023acriticalevaluation pages 27-27): Ronja Reinhardt and Thomas A Leonard. A critical evaluation of protein kinase regulation by activation loop autophosphorylation. eLife, Jul 2023. URL: https://doi.org/10.7554/elife.88210, doi:10.7554/elife.88210. This article has 43 citations and is from a domain leading peer-reviewed journal.
28. (rhyasen2015iraksignallingin pages 5-6): Garrett W. Rhyasen, Garrett W. Rhyasen, Garrett W. Rhyasen, D. Starczynowski, and D. Starczynowski. Irak signalling in cancer. British Journal of Cancer, 112:232-237, Oct 2015. URL: https://doi.org/10.1038/bjc.2014.513, doi:10.1038/bjc.2014.513. This article has 199 citations and is from a domain leading peer-reviewed journal.
29. (sadangi2020molecularcharacterizationand pages 18-22): Sushmita Sadangi, Arpita Mohanty, Mahismita Paichha, Suchismita Gouda, Ashis Saha, Surajit Das, and Mrinal Samanta. Molecular characterization and expressional modulation of irak1 as downstream signaling adaptor molecule of tlr-signaling pathways in labeo rohita following pamps stimulation and bacterial infections. Fish & Shellfish Immunology, 96:161-176, Jan 2020. URL: https://doi.org/10.1016/j.fsi.2019.11.064, doi:10.1016/j.fsi.2019.11.064. This article has 10 citations.
30. (seganish2016inhibitorsofinterleukin1 pages 1-6): W. Michael Seganish. Inhibitors of interleukin-1 receptor-associated kinase 4 (irak4): a patent review (2012-2015). Expert Opinion on Therapeutic Patents, 26:917-932, Jun 2016. URL: https://doi.org/10.1080/13543776.2016.1202926, doi:10.1080/13543776.2016.1202926. This article has 37 citations and is from a peer-reviewed journal.
31. (seganish2016inhibitorsofinterleukin1 pages 19-22): W. Michael Seganish. Inhibitors of interleukin-1 receptor-associated kinase 4 (irak4): a patent review (2012-2015). Expert Opinion on Therapeutic Patents, 26:917-932, Jun 2016. URL: https://doi.org/10.1080/13543776.2016.1202926, doi:10.1080/13543776.2016.1202926. This article has 37 citations and is from a peer-reviewed journal.
32. (seganish2016inhibitorsofinterleukin1 pages 22-26): W. Michael Seganish. Inhibitors of interleukin-1 receptor-associated kinase 4 (irak4): a patent review (2012-2015). Expert Opinion on Therapeutic Patents, 26:917-932, Jun 2016. URL: https://doi.org/10.1080/13543776.2016.1202926, doi:10.1080/13543776.2016.1202926. This article has 37 citations and is from a peer-reviewed journal.
33. (seganish2016inhibitorsofinterleukin1 pages 26-30): W. Michael Seganish. Inhibitors of interleukin-1 receptor-associated kinase 4 (irak4): a patent review (2012-2015). Expert Opinion on Therapeutic Patents, 26:917-932, Jun 2016. URL: https://doi.org/10.1080/13543776.2016.1202926, doi:10.1080/13543776.2016.1202926. This article has 37 citations and is from a peer-reviewed journal.
34. (seganish2016inhibitorsofinterleukin1 pages 30-34): W. Michael Seganish. Inhibitors of interleukin-1 receptor-associated kinase 4 (irak4): a patent review (2012-2015). Expert Opinion on Therapeutic Patents, 26:917-932, Jun 2016. URL: https://doi.org/10.1080/13543776.2016.1202926, doi:10.1080/13543776.2016.1202926. This article has 37 citations and is from a peer-reviewed journal.